Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma

Blood (2021) 138 (Supplement 1): 901.

https://doi.org/10.1182/blood-2021-148591

Published: 2021

Journal Articles

Prediction of Early Onset Cytokine Release Syndrome and Neurologic Events after Axicabtagene Ciloleucel in Large B-Cell Lymphoma Based on Machine Learning Algorithms

Qinghua Song, Tao Hu, Sattva S. Neelapu, Frederick L. Locke, Caron Jacobson, David B. Miklos, Olalekan O. Oluwole, Marie José Kersten, Max Topp, Jenny J. Kim, Kanwarjit Singh, Jorge Andrade, Lei Huang, Allen Xue, Marco Schupp, Myrna Nahas, Rhine R. Shen, Adrian Bot

Blood (2021) 138 (Supplement 1): 2833.

https://doi.org/10.1182/blood-2021-148580

Published: 2021

Journal Articles

Effects of Prior Exposure to Tec Kinase(BTK/ITK) Inhibitors on Kte-X19 Products

Irene Scarfò, Kathleen M.E. Gallagher, Mark B. Leick, Michael C. Kann, Justin Budka, Bharat Sowrirajan, Kim Nguyen, Rhine R. Shen, Adrian Bot, Marcela V. Maus

Blood (2021) 138 (Supplement 1): 3849.

https://doi.org/10.1182/blood-2021-146941

Published: 2021

Journal Articles

Profiling the Peripheral Blood Immune Cell Repertoire in Large-B Cell Lymphoma Patients Treated with CD19 CAR-T

Giulia Cheloni, Eleni Kanata, Dina Stroopinsky, Dimitra Karagkouni, Jessica J. Liegel, Daniela Torres, Joshua Hauser, Poorva Bindal, Anita G. Koshy, Yered Pita-Juarez, Adrian Bot, Mike Mattie, Justin Chou, Jacalyn Rosenblatt, David Avigan, Ioannis Vlachos

Blood (2021) 138 (Supplement 1): 2786.

https://doi.org/10.1182/blood-2021-151459

Published: 2021

Journal Articles

A Phase II Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Matthew J. Frigault, Kathleen M.E. Gallagher, Marc Wehrli, Betsy Valles, Keagan Casey, Kevin Lindell, Michael Trailor, Hana Cho, Jami L. Brown, Nora K. Horick, Justin Chou, Rhine R. Shen, Simone Filosto, Adrian Bot, Marcela V. Maus

Blood (2021) 138 (Supplement 1): 2814.

https://doi.org/10.1182/blood-2021-146927

Published: 2021

Journal Articles

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Blood (2021) 138 (Supplement 1): 1764.

https://doi.org/10.1182/blood-2021-148078

Published: 2021

Journal Articles

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

Blood (2021) 138 (12): 1081–1085.

https://doi.org/10.1182/blood.2021010930

Published: 2021

Includes: Supplemental data

Journal Articles

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Blood (2021) 138 (1): 11–22.

https://doi.org/10.1182/blood.2020009098

Published: 2021

Includes: Supplemental data

Journal Articles

Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)

Blood (2020) 136 (Supplement 1): 40–42.

https://doi.org/10.1182/blood-2020-134362

Published: 2020

Journal Articles

Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial

Michael Wang, MD, John M. Rossi, MS, Javier Munoz, MD, Andre H. Goy, MD, Frederick L. Locke, MD, Patrick M. Reagan, MD, Caron A. Jacobson, MD, Brian T. Hill, MD, Houston Holmes, Samantha Jaglowski, MD MPH, Weimin Peng, PhD, Lianqing Zheng, PhD, Xiang Fang, PhD, Allen Xue, PhD, Ioana Kloos, MD, Adrian Bot, MD PhD

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-136831

Published: 2020

Journal Articles

CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel

Sattva S Neelapu, MD, John M. Rossi, MS, Caron A. Jacobson, MD, Frederick L. Locke, MD, David B. Miklos, MD PhD, Patrick M Reagan, MD, Scott J Rodig, MD PhD, Lazaros J. Lekakis, MD, Ian W. Flinn, MD PhD, Lianqing Zheng, PhD, Francesca Milletti, PhD, Edmund Chang, PhD, Allen Xue, PhD, Vicki Plaks, PhD, Jenny J. Kim, MD MS, Adrian Bot, MD PhD

Blood (2019) 134 (Supplement_1): 203.

https://doi.org/10.1182/blood-2019-126218

Published: 2019

Journal Articles

2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma

Blood (2018) 132 (Supplement 1): 2967.

https://doi.org/10.1182/blood-2018-99-111368

Published: 2018

Journal Articles

Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

Jennifer Brudno, MD, Steven Hartman, Norris Lam, BS, David F. Stroncek, John M. Rossi, MS, Yueh-wei Shen, Allen Xue, PhD, Adrian Bot, MD PhD, Jennifer A Kanakry, MD, Steven Z. Pavletic, MD, Lekha Mikkilineni, MD, Mark Roschewski, MD, Robert M. Dean, MD, Jeremy J. Rose, MS, Rashmika Patel, Brenna Hansen, Steve A. Rosenberg, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2018) 132 (Supplement 1): 697.

https://doi.org/10.1182/blood-2018-99-113731

Published: 2018

Journal Articles

Analysis of CAR-T and Immune Cells within the Tumor Micro-Environment of Diffuse Large B-Cell Lymphoma Post CAR-T Treatment By Multiplex Immunofluorescence

Pei-Hsuan Chen, PhD, Mikel Lipschitz, M.S., Kyle Wright, MD, PhD, Philippe Armand, MD PhD, Caron A. Jacobson, MD MMSc, Zachary J. Roberts, MD, PhD, John M. Rossi, MS, Adrian Bot, MD PhD, William Y. Go, MD PhD, Scott J Rodig, MD

Blood (2018) 132 (Supplement 1): 678.

https://doi.org/10.1182/blood-2018-99-113644

Published: 2018

Journal Articles

Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL

John Rossi, Patrick Paczkowski, Yueh-Wei Shen, Kevin Morse, Brianna Flynn, Alaina Kaiser, Colin Ng, Kyle Gallatin, Tom Cain, Rong Fan, Sean Mackay, James R. Heath, Steven A. Rosenberg, James N. Kochenderfer, Jing Zhou, Adrian Bot

Blood (2018) 132 (8): 804–814.

https://doi.org/10.1182/blood-2018-01-828343

Published: 2018

Includes: Supplemental data

Journal Articles

Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Blood (2017) 130 (Supplement 1): 578.

https://doi.org/10.1182/blood.V130.Suppl_1.578.578

Published: 2017

Journal Articles

Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Frederick L. Locke, MD, Jason R. Westin, MD, David B. Miklos, MD PhD, Alex F. Herrara, MD, Caron A. Jacobson, MD, Jennifer Lee, John M. Rossi, MS, Adrian Bot, MD PhD, Allen Xue, PhD, Lynn Navale, MS, Jeff S. Aycock, Jeffrey S. Wiezorek, MD MS, Zachary J. Roberts, MD PhD

Blood (2017) 130 (Supplement 1): 2826.

https://doi.org/10.1182/blood.V130.Suppl_1.2826.2826

Published: 2017

Journal Articles

Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

Blood (2017) 130 (Supplement 1): 1547.

https://doi.org/10.1182/blood.V130.Suppl_1.1547.1547

Published: 2017

Journal Articles

High Rates of Minimal Residual Disease-Negative (MRD−) Complete Responses (CR) in Adult and Pediatric and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Treated With KTE-C19 (Anti-CD19 Chimeric Antigen Receptor [CAR] T Cells): Preliminary Results of the ZUMA-3 and ZUMA-4 Trials

Blood (2016) 128 (22): 2803.

https://doi.org/10.1182/blood.V128.22.2803.2803

Published: 2016

Journal Articles

A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1

Sattva S. Neelapu, MD, Frederick L. Locke, MD, Nancy L Bartlett, MD, Tanya Siddiqi, MD, Caron A. Jacobson, MD, Jason R. Westin, MD, Julio C. Chavez, MD, Armin Ghobadi, MD, Alex F Herrera, MD, Ann S. LaCasce, MD, Adrian Bot, MD PhD, John M. Rossi, MS, Yizhou Jiang, PhD, Jeff S. Aycock, BA, Meg Elias, RN,BSN, Jeff Wiezorek, MD MS, William Y. Go, MD PhD

Blood (2016) 128 (22): 998.

https://doi.org/10.1182/blood.V128.22.998.998

Published: 2016

NARROW

TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma

Prediction of Early Onset Cytokine Release Syndrome and Neurologic Events after Axicabtagene Ciloleucel in Large B-Cell Lymphoma Based on Machine Learning Algorithms

Effects of Prior Exposure to Tec Kinase(BTK/ITK) Inhibitors on Kte-X19 Products

Profiling the Peripheral Blood Immune Cell Repertoire in Large-B Cell Lymphoma Patients Treated with CD19 CAR-T

A Phase II Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)

Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial

CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel

2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma

Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

Analysis of CAR-T and Immune Cells within the Tumor Micro-Environment of Diffuse Large B-Cell Lymphoma Post CAR-T Treatment By Multiplex Immunofluorescence

Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL

Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only